To assess the power of our ddPCR assay for longitudinal monitoring of TERT breakpoints in patient samples, we analyzed tumor, blood, and BM samples from three patients with TERT-rearranged high-risk neuroblastoma (P2, P3, and P4; Supplementary Tables S1 and S4). This evidence concerns the gene TERT and neuroblastoma.